Gavi, the Vaccine Alliance
Gavi, the Vaccine Alliance is a public-private partnership whose task it is to help save children's lives and protect people's health by providing easy access to immunisations and by improving health systems. The Vaccine Alliance aims to achieve this by boosting national immunisation programmes, introducing new vaccines and establishing sustainable health funding.
The Global Alliance for Vaccines and Immunization, as it was originally called, was founded in 2000 and is now known simply as Gavi, the Vaccine Alliance. Gavi unites all key decision-makers on immunisation matters in a collaborative partnership. These key decision-makers include the governments of industrialised and developing countries, WHO, UNICEF, the World Bank, the Bill and Melinda Gates Foundation, manufacturers of vaccines from industrialised countries and emerging economies, as well as public health bodies and non-governmental organisations. Gavi is based in Geneva and, since 2009, has been registered there as a foundation in accordance with Swiss law.
The Vaccine Alliance is another means of providing funding under international cooperation, in addition to already existing bilateral and multilateral instruments of funding. The major share of Gavi’s funds is spent on vaccines to combat the following diseases: hepatitis B, haemophilus influenzae type B (Hib), yellow fever, tetanus, whooping cough, measles and diphtheria. In addition, Gavi provides support for vaccination campaigns against pneumococcal infections and rotaviruses. Pneumococci are the main cause of pneumonia, and rotaviruses cause severe diarrhoeal diseases. Pneumonia and diarrhoeal diseases are the main causes of child mortality in developing countries.
Through their joint activities, the partners within Gavi are making a direct contribution towards helping to achieve Millennium Development Goal Number 4, the reduction of child mortality. According to calculations by the World Health Organization, the immunisation programmes that the Gavi Alliance has carried out since its launch in 2000 have helped to prevent more than 6 million deaths.
The BMZ has been supporting the Vaccine Alliance since 2006. Between 2006 and 2009, Germany made available a total of 12 million euros for Gavi’s work. In 2010, Germany provided funding amounting to four million euros, and, since then, the amounts have been increasing further each year – to 20 million euros in 2011 and 30 million euros in 2012, bringing its overall commitment for the period 2011 to 2015 to 156 million euros. In June 2014, Germany confirmed its intention to bring Gavi’s funding level from 30 million euros a year to 38 million euros a year from 2014.
You can find extensive information on the Gavi replenishment conference and how Germany is supporting Gavi here:
Gavi, the Vaccine Alliance
2 Chemin des Mines
Phone: +41 / 22 / 9 09 65 00
Fax: +41 / 22 / 9 09 65 50